


LTM

POV

Outcreating for Patient Centricity

—

Accelerating Innovation in Health & Life Sciences in the AI Era




Table of Contents

Introduction	3
The Urgency for Patient-Centric Transformation	4
Patient Centricity Remains Hard to Operationalize in Health and Life Sciences	4
Shift the Focus from Systems to Patient-Oriented Outcomes	6
AI as an Enabler of Patient-Centric Innovation	8
How AI Changes the Patient Equation	8
The Hard Part Leaders Need to Solve	8
The Horizon, Organized as Decision Lanes	9
Change How Decisions Get Made Across the Health and Life Sciences Paradigm	10
Future Outlook	10
Conclusion	11
References	12
About the Authors	12

Introduction

Patient centricity has become one of the most widely shared ambitions across the health and life sciences industries. Whether we are talking about pharmaceutical companies, medical device manufacturers, healthcare providers, or payers, there is a universal recognition that the patient must be at the center of how healthcare is designed, delivered, and experienced.

Leaders across the ecosystem understand this. They recognize that better patient experiences, clearer care journeys, and stronger outcomes benefit not just patients and caregivers, but also providers, regulators, and health sciences organizations themselves.

Yet despite this shared ambition, **operationalizing patient centricity remains difficult.**

Over the past decade, many transformation initiatives have focused on modernizing systems, improving operational efficiency, ensuring compliance, and digitizing workflows. These investments have been necessary and valuable. But reality is that the **patient journey still cuts across multiple systems, organizations, and decision points.**

Even well-intentioned transformation programs often struggle to embed patient centricity consistently across the entire ecosystem.

Today's conversation focuses on how we can move from **talking about patient centricity in healthcare to truly enabling it, using creative technology and innovative operating models.**

The discussion that follows is organized around five linked moves:

- Why the urgency for patient-centric transformation
- Why patient centricity remains difficult to operationalize in real programs
- What changes when organizations shift from system roadmaps to patient-oriented outcomes
- How AI can enable proactive, personalized, and outcome-led decisions across the value chain
- What readiness looks like when patient focus becomes operational reality, supported by explainability, trust, and speed in regulated environments

The Urgency for Patient-Centric Transformation

Patients today are more informed, more digitally connected, and more involved in their care decisions than ever before. They expect transparency, personalization, and seamless experiences similar to what they encounter in other industries.

It is to fulfill these expectations that organizations are striving to deliver better outcomes, improved access, and more personalized care, often under the constraints of cost and pricing pressures, resource stretch, and regulatory diligence.


Delivering on these expectations is not just about increasing investments or adopting the latest tools. It is about reimagining how technology, data, and human insight come together to solve real healthcare problems.

Patient Centricity Remains Hard to Operationalize in Health and Life Sciences

We've observed that many organizations struggle to translate patient-centricity from a stated aspiration into a practice that consistently influences decisions, incentives, and accountability across the enterprise.

Over the past decade, most healthcare digital transformations have concentrated on platforms and workflow modernization. Organizations invested heavily in upgrading core systems, standardizing processes, strengthening compliance frameworks, and improving operational controls.

These initiatives delivered meaningful value. At the same time, they reinforced familiar patterns:



In one health plan member-engagement program, we recall a conversation that followed a major modernization milestone. The program improved service workflows, communication coverage, and operational turnaround. The dashboard looked strong. Timelines were met, efficiency improved, and service metrics moved in the right direction.

Yet members were still struggling at the same points. They could get answers, but they still found it difficult to understand coverage, identify the next step, and move from query resolution to actual care follow-through.

The reason was clear. The transformation had improved systems within individual functions, but it had not fully changed ownership or accountability for the member journey across the value chain.

Why Patient Centricity Stays Hard to Operationalize




Figure 1: Five structural reasons patient centricity remains hard to operationalize in health and life sciences.

When leaders recognize that modernization is only the starting point, they can shift from system-led roadmaps to patient-oriented outcomes and begin measuring real patient impact in their business.



Shift the Focus from Systems to Patient-Oriented Outcomes

A system can go live, and yet the patient journey can still feel fragmented. That disconnect explains why modernization alone does not always translate into meaningful patient impact.

Digital programs often celebrate platform launches, workflow automation, and compliance milestones. These achievements matter and frequently deliver real operational value.

What they do not automatically guarantee, however, is easier access to care, stronger follow-through, or more consistent outcomes in the real world. That is where the focus must shift. The true measure of progress is not whether systems have changed, but whether patient-oriented outcomes have improved alongside them.

Challenge the Legacy Mindset

Modernization should be viewed as an enabler of impact, not as the impact itself.

If patient centricity is the real goal, success must ultimately be defined in patient terms.

Otherwise, operational metrics will continue to dominate transformation agendas, not because they matter more, but because they are easier to measure and reward.

Patient impact must move from the periphery to the center of the performance scorecard.

Build Outcome-Oriented Roadmaps

A more powerful starting point is to ask a different question: **Which patient outcomes must improve, and what must change across the organization to make that happen?**

Once those outcomes are clear, transformation roadmaps can be designed backward across data, operating models, and decision processes.

A practical outcome set could include:

- Faster access to the right intervention or therapy
- Higher adherence and stronger follow-through across care plans
- Earlier detection of drug safety risks
- More consistent quality across care settings

When outcomes anchor the roadmap, investments become more focused. Resources move toward initiatives that improve patient impact rather than toward those that appear productive.

Reset KPIs So Patient Impact Is Not Optional

Metrics shape desired attitudes and ensure they are operational and not just aspirational- because teams usually deliver what gets rewarded.

Patient experience and outcomes, however, often sit outside the core operational scorecard. The answer is not to introduce dozens of new metrics. It is to select a small number of patient outcome measures, link them to leading operational indicators, and assign
clear ownership.

For example, faster therapy access can be tied to authorization cycle time, care coordination delays, or onboarding completion. Better adherence can be linked to follow-up completion, patient support engagement, and early drop-off signals. Improved safety can be linked to how quickly emerging risk signals are detected, escalated, and acted upon. .

When patient impact becomes part of how performance is measured, it naturally becomes part of how decisions are made.

Tie ROI to Patient Impact

Efficiency gains will always matter! And for that, patient-centric innovation must also demonstrate that it can drive measurable patient impact.

We recall a manufacturing facility producing temperature-sensitive injectables where reliability "unexpectedly" became the patient story. Their production quality performance metrics focused on traditional operational KPIs.

A manufacturing anomaly in aseptic processing did not initially appear alarming in operational dashboards as fluctuations remained within validated tolerance bands. But downstream, it triggered additional quality reviews, extended investigations, and conditional holds, ultimately leading to supply disruptions, therapy delays, and treatment disruptions. What began as a statistically insignificant manufacturing signal ultimately disrupted continuity of care.

That moment changed the conversation. The team responded by treating predictive quality, supply reliability, and availability as patient outcome drivers, not just manufacturing metrics.

Because the real cost of late surprises was no longer measured only in operational rework, it was measured in patient impact.



AI as an Enabler of Patient-Centric Innovation

AI is no magic potion that infuses patient centricity into Life Sciences or Healthcare organizations. But AI can significantly accelerate patient-centric innovation when leaders deliberately apply it and connect it to outcomes that matter to patients.

Whether in clinical trials, pharmacovigilance, care delivery, health plan member needs, or patient support programs, issues often become visible only after they have already affected patient experience or outcomes. By the time those signals surface, the opportunity for early intervention is frequently lost.

AI has the potential to change that rhythm.

By continuously analyzing patient signals across clinical, operational, and real-world data sources, AI can help teams detect emerging risks earlier, anticipate safety or adherence issues before they escalate, and enable more proactive, personalized, and outcome-oriented interventions.

This is where the opportunity becomes real: the shift begins when AI-enabled decisions are made in a trustworthy, explainable, and transparent manner.

How AI Changes the Patient Equation

AI becomes meaningful when it turns patient signals into decisions at the point they matter.


- It can surface risk patterns earlier, so interventions happen before a deterioration, not after an escalation.
- Avoiding broad averages, it can personalize pathways based on real-world signals.
- It can connect context across functions, so decisions stop getting made in a partial view.

This is also where Business Creativity shows up in practice. The advantage is rarely a model by itself. Advantage comes from combining human judgment about patient reality with intelligent systems that maintain consistent, measurable, and accountable decisions.

The Hard Part Leaders Need to Solve

Patient-centric AI is constrained by three questions that cannot be hand-waved:

- **Explainability:** Can a clinician, quality leader, or regulator understand why the system recommended a decision?
- **Trust:** Can teams prove the system behaves safely across populations, settings, and edge cases?
- **Speed:** Can insights arrive in time to change outcomes, or do they show up after the window closes?



The Horizon, Organized as Decision Lanes

Patient-centric innovation spans a wide horizon. It stays manageable when you group it by decision lanes and anchor each lane to patient outcomes.




Figure 2: Six AI-enabled decision lanes that shift patient centricity from intent to measurable outcomes.

In one clinical trial program we observed, the customer made a subtle but important shift. Instead of treating patient recruitment and retention as operational challenges, they began to view them as a patient experience problem.

Using predictive signals and historical trial data, our team helped analyze where patient burden is likely to increase, where dropout risk might spike, and where representation across populations could suffer if the study followed its original design.

Those insights allowed the team to adjust the protocol before the trial launched, reducing participation friction, simplifying visit schedules, and addressing barriers that could discourage enrolment or continued participation.

The result was not just smoother recruitment. The trial remained closer to real-world patient diversity, strengthening both participation and the quality of the evidence generated.

The most important change, however, was not technology. It was the decision posture. Patient needs were incorporated into the study design from the beginning, rather than as a constraint discovered too late once the trial was underway.

Change How Decisions Get Made Across the Health and Life Sciences Paradigm

Patient outcomes sit at the intersection of clinical reality, operational execution, quality, supply reliability, and economics.

Decisions have traditionally followed a familiar rhythm. Experts apply judgment, teams rely on historical data, and leaders revisit priorities through periodic governance cycles. That approach protects safety and reduces risk, but also creates a lag! Because patient signals change faster than review cycles.


AI changes the model when organizations use it to build **continuous intelligence rather than episodic analysis.** Creative technology then becomes the connective layer that synchronizes data, detects patterns, and supports operational and clinical choices based on predicted outcomes.

Future Outlook

Patient centricity will eventually stop being a differentiator. It will simply become expected behavior. That shift is already underway.

Patients, regulators, and advocacy groups are asking tougher questions about how healthcare decisions are made, how patient data is used, and who remains accountable when outcomes fall short.

As transparency increases, trust will no longer come from organizational claims or marketing narratives. It will come from **decision transparency and consistent results in real-world settings.**





AI and creative technology will shorten learning cycles across the health and life sciences value chain. Evidence will move faster. Feedback loops will tighten. What used to take quarters to detect and correct will move closer to days or weeks. That speed will reward organizations that can explain decisions clearly, govern them responsibly, and act without delay when risk signals appear.

We advise three bold moves that separate those organizations from everyone else:

1

Redefine Success Around Patient Impact

Patient outcomes and patient experience cannot remain secondary indicators. Leaders need to elevate a small set of patient impact measures into the core scorecard and treat them as outcomes that guide investment, prioritization, and trade-offs.

2

Invest Differently and into the Future

Investment decisions will shift toward patient value creation. Leaders will fund initiatives that improve access, strengthen continuity of care, increase adherence, enhance safety monitoring, and ensure reliability across the chain.

3

Reimagine the Workplace for Accountability and Experience Ownership

Patient-centric enterprises will not win through isolated programs. They will win through enterprise-level culture and decision accountability. Teams will know who owns the journey, who acts on signals, and how conflicts get resolved when patient impact competes with efficiency or risk posture.

Conclusion

The future of health and life sciences will belong to organizations that **Outcreate traditional operating models** by redesigning decision-making around the patient.

Patient-centric innovation will be defined by faster therapy access, fewer avoidable care delays, stronger adherence, earlier safety interventions, and more reliable therapy availability across the value chain.

At LTM, we call this **Business Creativity,** where human ingenuity and intelligent technology come together- to innovate, to solve, to turn ideas real.

References

1. Healthcare systems need to better respond to patients' needs, finds first international OECD patient survey, The Organization for Economic Co-operation and Development, February 20, 2025:

https://www.oecd.org/en/about/news/press-releases/2025/02/healthcare-systems-need-to-better-respond-to-patients-needs-finds-first-international-oecd-patient-survey.html

About the Authors



Manikandesh (Mani) Venkatachalam

SVP and Chief Business Officer – Health and Life Sciences, LTM

Manikandesh (Mani) Venkatachalam is Chief Business Officer at LTM, where he drives strategic growth and operational excellence across the Travel, Hospitality, Healthcare, and Life Sciences verticals. He brings deep experience in executive partnerships, large-scale digital transformation, and market expansion. Before joining LTM, he held senior leadership roles at Ascendion, Zensar Technologies, Genpact, Cognizant, and Mindtree, where he led growth, client relationships, and business transformation across sectors.



Vinod Sanjay

Head of Consulting – Health and Life Sciences, LTM

Vinod Sanjay leads the Health and Life Sciences consulting practice at LTM. As a senior executive and strategic advisor, he brings deep expertise spanning Health Sciences, AI, and digital transformation. Vinod is recognized for designing outcome-driven strategies and building scalable, emerging-technology solutions with measurable business and clinical impact. He partners with clients to shape the future of health through pragmatic innovation, simplified intelligence, human-centered trust, and long-term value creation.

LTM is a global technology services and consulting company and the business creativity partner to the world's largest and most disruptive companies. We bring human insights and intelligent systems together to help enterprises across industries rewire their business models, accelerate innovation, and drive AI-centric growth. With our integrated operations, transformation, and business AI services, we design and deliver solutions that create new productivity paradigms and new roads to value. Together with 87,000 employees across 40 countries and our global network of hyperscaler partners, LTM — A Larsen & Toubro company — owns business outcomes for over 700 clients, helping them to not simply outperform the market, but to Outcreate it.

© LTM